Skip Navigation
Skip to contents

Diabetes Metab J : Diabetes & Metabolism Journal

Search
OPEN ACCESS

Articles

Page Path
HOME > Diabetes Metab J > Volume 31(1); 2007 > Article
Original Article Prevention of Diabetes by Fenofibrate in OLETF Rats: Hepatic Mechanism for Reducing Visceral Adiposity.
Hye Jeong Lee, Mi Kyoung Park, Kyung Il Lee, Young Jun An, Ji Min Kim, Ja Young Park, Young Han, Sook Hee Hong, Sun Seob Choi, Young Hyun Yoo, Joon Duk Suh, Duk Kyu Kim
Diabetes & Metabolism Journal 2007;31(1):63-74
DOI: https://doi.org/10.4093/jkda.2007.31.1.63
Published online: January 1, 2007
  • 2,177 Views
  • 19 Download
  • 4 Crossref
  • 0 Scopus
1Internal Medicine Department, Medical College of Dong-A University, Korea.
2Pharmacology Department, Medical College of Dong-A University, Korea.
3Internal Medicine Department, Baptist Hospital, Korea.
4Internal Medicine Department, Bando Hospital, JinJu, Korea.
5Internal Medicine Department, Hanseo Hospital, Korea.
6Internal Medicine Department, Dong-A University Medical Center, Korea.
7Graduate School, Dong-A University, Korea.
8Pathology Department, Medical College of Dong-A University, Korea.
9Diagnostic Radiology Department, Medical College of Dong-A University, Korea.
10Anatomy Department, Medical College of Dong-A University, Korea.
11Physiology Department, Medical College of Dong-A University, Korea.

BACKGROUND
The aim of this study is to evaluate the hepatic mechanism of fenofibrate that has the diabetes protective action in rats. METHODS: We chose OLETF rats and divided them into three groups. Fenofibrate (DF) group was fed with diet and fenofibrate (300 mg/kg/day). Paired feeding (Dd) group and free diet (DD) group were fed with diet. After 36 weeks of treatment, all the rats were sacrificed. RESULTS: The fasting blood glucose level of DF group (8.5 +/- 0.9 mmol/L) showed normal. The fasting blood glucose level of Dd group (22.4 +/- 3.0 mmol/L) and DD group (16.9 +/- 3.7 mmol/L) showed significantly increased than that of DF group (P < 0.01, respectively). The body weight, visceral adipose tissue and subcutaneous adipose tissue of DF group were significantly decreased compared to those of Dd and DD groups (P < 0.01, P < 0.05, P < 0.05). DF group showed significantly increased state-3 respiration rate, ATP synthetic activity, state-4 respiration rate and their blood beta-keton body levels than those of control groups (P < 0.01, respectively). DF group showed normal morphology of hepatocytes but DD and Dd groups showed hepatic steatosis with mitochondrial swellings. CONCLUSION: Chronic fenofibrate treatment prevents the development of diabetes in OLETF rats with inhibiting gain of body weight and abdominal adiposity. The hepatic mechanism for reducing visceral adiposity is that fenofibrate leads to increasing oxidative phosphorylation, uncoupling and ketogenesis as well as increasing beta-oxidation of fatty acids. Moreover, fenofibrate treatment prevents the development of hepatic steatosis.

  • Cite
    CITE
    export Copy
    Close
    Download Citation
    Download a citation file in RIS format that can be imported by all major citation management software, including EndNote, ProCite, RefWorks, and Reference Manager.

    Format:
    • RIS — For EndNote, ProCite, RefWorks, and most other reference management software
    • BibTeX — For JabRef, BibDesk, and other BibTeX-specific software
    Include:
    • Citation for the content below
    Prevention of Diabetes by Fenofibrate in OLETF Rats: Hepatic Mechanism for Reducing Visceral Adiposity.
    Korean Diabetes J. 2007;31(1):63-74.   Published online January 1, 2007
    Close
Related articles
Lee HJ, Park MK, Lee KI, An YJ, Kim JM, Park JY, Han Y, Hong SH, Choi SS, Yoo YH, Suh JD, Kim DK. Prevention of Diabetes by Fenofibrate in OLETF Rats: Hepatic Mechanism for Reducing Visceral Adiposity.. Diabetes Metab J. 2007;31(1):63-74.
DOI: https://doi.org/10.4093/jkda.2007.31.1.63.

Diabetes Metab J : Diabetes & Metabolism Journal